ZVSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZVSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.
ZyVersa Therapeutics's Days Sales Outstanding for the
three
months ended in Mar. 2024 was .
ZyVersa Therapeutics's Days Inventory for the
three
months ended in Mar. 2024 was .
ZyVersa Therapeutics's Days Payable for the
three
months ended in Mar. 2024 was .
Therefore, ZyVersa Therapeutics's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2024 was 0.00.
The historical data trend for ZyVersa Therapeutics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZyVersa Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Cash Conversion Cycle | - | - | - | - |
ZyVersa Therapeutics Quarterly Data | |||||||||||||
Dec20 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Conversion Cycle | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, ZyVersa Therapeutics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where ZyVersa Therapeutics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
ZyVersa Therapeutics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | + | - | ||||
= | 0.00 |
ZyVersa Therapeutics's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | + | - | ||||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZyVersa Therapeutics (NAS:ZVSA) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Thank you for viewing the detailed overview of ZyVersa Therapeutics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Pablo A. Guzman | officer: Chief Medical Officer | C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326 |
Gregory Gene Freitag | director | 13631 PROGRESS BLVD., ALACHUA FL 32615 |
Katrin Rupalla | director | 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
James Sapirstein | director | 1517 SAN JACINTO, HOUSTON TX 77002 |
Stephen C. Glover | director, officer: Chief Executive Officer | 108 DOCKSIDE CIRCLE, WESTON FL 33327 |
Labella Nicholas A. Jr. | officer: Chief Scientific Officer | C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235 |
Peter Wolfe | officer: Chief Financial Officer | C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326 |
Karen A. Cashmere | officer: Chief Commercial Officer | C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326 |
Min-chul Park | director | C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326 |
Incon Co., Ltd. | 10 percent owner | 4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042 |
Robert G Finizio | director | 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487 |
Raj Mehra | director | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
David S. Briones | director, officer: Chief Financial Officer | C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056 |
Daniel J. O'connor | director, officer: Chief Executive Officer | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
A.g.p. / Alliance Global Partners Corp. | 10 percent owner | 88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880 |
From GuruFocus
By Marketwired • 06-28-2023
By sperokesalga sperokesalga • 06-20-2023
By Marketwired • 10-04-2023
By Marketwired • 09-12-2023
By sperokesalga sperokesalga • 06-13-2023
By Marketwired • 07-14-2023
By Marketwired • 10-18-2023
By sperokesalga sperokesalga • 06-06-2023
By GlobeNewswire GlobeNewswire • 05-19-2023
By sperokesalga sperokesalga • 04-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.